E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with J
>
Issuers starting with J, SP only
>
All stories on Juno Therapeutics, Inc.
>
Stories on Juno Therapeutics, Inc., SP only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Juno Therapeutics, Inc.
1/5/2018
SP
New Issue: Credit Suisse prices $3.9 million autocallable securities on Juno Therapeutics
10/6/2017
SP
New Issue: Barclays prices $3.2 million of trigger jump autocallables tied to Juno
9/28/2017
SP
Barclays to price jump securities with autocall feature linked to Juno
7/28/2015
SP
New Issue: JPMorgan prices $756,000 autocallable contingent interest notes linked to Juno Therapeutics
7/23/2015
SP
JPMorgan’s autocalls tied to Juno pay 31% contingent coupon, but know your stock, sources say
7/22/2015
SP
JPMorgan plans contingent interest autocallables on Juno Therapeutics
5/21/2015
SP
New Issue: JPMorgan prices $2 million one-year digital notes on Juno Therapeutics
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
